Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Liabilities and Shareholders Equity (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Liabilities and Shareholders Equity for 8 consecutive years, with $18.2 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 7.25% to $18.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $78.3 million through Dec 2025, up 10.51% year-over-year, with the annual reading at $18.6 million for FY2025, N/A changed from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $18.2 million at Outlook Therapeutics, down from $18.6 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $22.4 million in Q2 2025, with the low at $17.0 million in Q4 2024.